#中國醫藥

AstraZeneca Secures $1.5B Licensing Deal for Dizal Pharmaceutical's Lung Cancer Therapy

AstraZeneca has agreed to pay up to $1.5 billion for global rights to Dizal Pharmaceutical's targeted lung cancer drug Sunvozertinib, emphasizing global interest in Chinese oncology assets.

Williams·Jul 14, 2026·2 min read